[Intrauterine transfusion in fetal alloimmunothrombocytopenia: comparison of maternal and fetal weight-adjusted IgG therapy with exclusive fetal thrombocyte transfusion].
Fetal alloimmune thrombocytopenia is caused by maternal immunization against a fetal platelet antigen and transplacental transfer of the antibody into the fetal circulation. Since 10-20% of the fetuses or newborns are threatened by intracranial hemorrhages, early management is required. Fetal blood sampling should be started between the 20th and 22nd week of gestation to assess fetal phenotype and platelet count. Different concepts to elevate the fetal platelet count have been discussed: maternal intravenous immunoglobulins, fetal intravenous immunoglobulins, or only repeated fetal platelet transfusions. Our investigations suggested that platelet transfusions in short intervals appear to be the only effective regimen to increase platelet counts in thrombocytopenic fetuses at risk.
Giers
G
G
Institut für Hämostaseologie und Transfusionsmedizin, Heinrich-Heine-Universität Düsseldorf, Deutschland.
Kroll
H
H
Hoch
J
J
Bald
R
R
Bauer
H
H
Kiefel
V
V
Hansmann
M
M
Hanfland
P
P
Mueller-Eckhardt
C
C
Scharf
R E
RE
D001724:Birth Weight; D001792:Blood Platelets / Q000276:immunology*; D001805:Blood Transfusion, Intrauterine; D005260:Female; D005865:Gestational Age; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007231:Infant, Newborn; D007518:Isoantibodies / Q000097:blood*; D010976:Platelet Count; D017713:Platelet Transfusion; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000276:immunology / Q000628:therapy*; D013921:Thrombocytopenia / Q000276:immunology / Q000628:therapy*; D016896:Treatment Outcome
D007074:Immunoglobulin G; D007518:Isoantibodies